FDA Approval of Nucala for Treatment of Severe Asthma in Children
Dr. Jonathan Steinfeld, global clinical lead for the GSK mepolizumab pediatric asthma indication discusses the recent FDA approval of GSK’s Nucala (mepolizumab) the only biologic for use in children as young as 6 years old that have severe eosinophilic asthma.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Asthma. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Asthma and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Asthma?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Jonathan Steinfeld is the global clinical lead for the GSK mepolizumab pediatric asthma indication as well as a board-certified pediatric pulmonologist. Prior to joining GSK, Dr. Steinfeld was in academic practice for many years at St. Christopher’s Hospital for Children. At St. Christopher’s, his practice included severe asthma, cystic fibrosis, technology-dependent children, and airway malformations.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
